Can Vepotolizumab/Urova be discontinued after use?

Polatuzumab/Polatuzumab is an antibody-conjugated drug targeting CD79b. Its therapeutic goal is to inhibit the growth and spread of malignant non-Hodgkin lymphoma cells by precisely acting on B cells. In actual clinical practice, patients and their families are often concerned about one question: whether the drug can be stopped after taking it. The answer needs to be combined with the patient's condition, efficacy evaluation and the doctor's comprehensive judgment.

Normally, velpotuzumab is not a drug that can be used as a "radical cure" after one-time or short-term use. Its usage cycle is mostly based on treatment courses, and each treatment course is usually spaced about three weeks apart. Doctors will evaluate the patient's response to the drug through imaging examinations, hematological indicators and pathology after each course of treatment. If a patient experiences significant relief after multiple courses of treatment, the doctor may consider reducing the dose, extending the interval, or even temporarily discontinuing the drug, but only if the patient's condition is stable and continuous follow-up is possible.

On the other hand, if the patient experiences intolerable side effects during use, such as decreased platelets, neurotoxicity, or increased risk of infection, doctors will also adjust the plan according to the specific situation, including discontinuing the drug or switching to other drugs. The treatment strategy of vepotuzumab emphasizes individualization. Whether to stop the drug must be done under the guidance of a professional doctor. It is not recommended that patients decide the time to stop the drug by themselves.

It is worth noting that due to the biological characteristics and high risk of recurrence of lymphoma, even if symptoms are relieved or imaging shows tumor shrinkage, vepotuzumab is not equivalent to a "curative drug", and patients still need regular follow-up and reexamination. This means that management after drug withdrawal is equally important. Doctors will use dynamic monitoring and necessary auxiliary treatment to minimize the risk of recurrence and ensure long-term benefit for patients.

Reference materials:https://www.drugs.com/polivy.html